Notice 2 Jul 2025 small business administration, financial assistance, california, economic injury disaster loan, civil unrest

💰Economic Injury Disaster Loan Notice for California Businesses

This is a notice of an Economic Injury Disaster Loan (EIDL) declaration for the State of California dated June 27, 2025. Incident: Los Angeles County Civil Unrest.

Learn More
Notice 2 Jul 2025 regulatory compliance, postal service, international shipping, negotiated service agreements

📦Notice on Priority Mail International Service Agreement Changes

The Postal Service gives notice of filing a request with the Postal Regulatory Commission to add a Priority Mail Express International, Priority Mail International & First-Class Package International Service contract to the list of Negotiated Service Agreements in the Competitive Product List in the Mail Classification Schedule.

Learn More
Rule 2 Jul 2025 regulatory compliance, administrative practice and procedure, reporting and recordkeeping requirements, manufactured housing, department of energy, energy conservation, housing standards, buildings and facilities, enforcement procedures

🏠Energy Conservation Standards Compliance Date Amendments Explained

The U.S. Department of Energy (DOE) is publishing this rule to amend the compliance date for its manufactured housing energy conservation standards. Previously, manufacturers had to comply with these standards on and after July 1, 2025, for Tier 2 homes and 60 days after the issuance of enforcement procedures for Tier 1 homes. DOE is delaying the Tier 2 compliance date to allow DOE more time to consider the proposed enforcement procedures and comments submitted, and to evaluate appropriate next steps that provide clarity for manufacturers and other stakeholders.

Learn More
Notice 2 Jul 2025 regulations, fda, pharmaceutical, patent extension, human biological products, winrevair

💊FDA Patent Extension Notice for WINREVAIR

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for WINREVAIR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

Learn More
Notice 2 Jul 2025 information collection, treasury, insurance, fiscal service, surety

📝Proposed Collection of Information

The Department of the Treasury, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995. Currently the Bureau of the Fiscal Service within the Department of the Treasury is soliciting comments concerning the States Where Licensed for Surety.

Learn More
Notice 2 Jul 2025 fda, drug development, pharmaceutical industry, guidance, clinical trials, myelodysplastic syndromes

💊FDA Guidance on Developing Treatment for Myelodysplastic Syndromes

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Myelodysplastic Syndromes: Developing Drug and Biological Products for Treatment." The purpose of this guidance is to assist sponsors in the clinical development of drug and biological products for the treatment of the myelodysplastic syndromes (MDS). Specifically, this guidance addresses FDA's current thinking regarding the overall development program and clinical trial designs for the development of drug and biological products to support an indication of treatment of MDS. This guidance will focus specifically on development of drug and biological products that are considered disease-modifying and, therefore, will not cover products considered supportive only (e.g., erythropoiesis-stimulating agents). Furthermore, the guidance will not address drug development for MDS/myeloproliferative neoplasms, such as chronic myelomonocytic leukemia, which are considered a separate class of myeloid neoplasms.

Learn More
Notice 2 Jul 2025 regulatory compliance, healthcare, fda, biopharmaceutical, patent extension

💊FDA Notice on Patent Extension for REBYOTA Drug

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REBYOTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

Learn More
Notice 2 Jul 2025 international trade, china, commerce department, subsidy rates, active anode material, countervail duties

⚖️Amended Determination of Countervailing Duties on Anode Materials

The U.S. Department of Commerce (Commerce) is amending the preliminary affirmative countervailing duty (CVD) determination for active anode material from the People's Republic of China (China) to correct significant ministerial errors.

Learn More
Notice 2 Jul 2025 compliance, regulations, international organizations, u.s. department of state, travel restrictions, foreign missions act

🌍Impact of Foreign Missions Act on International Organizations 2025

The Department of State's notice details the application of the Foreign Missions Act to personnel of international organizations, including those not recognized by the U.S. The determination aims to ensure efficient operations and compliance with international law, emphasizing the necessary requirements for members of these official missions.

Learn More
Notice 2 Jul 2025 regulatory compliance, employment initiatives, data collection, social security, homeless services, supportive housing

🏠SSA Notice on Data Collection for Employment Initiatives

The Social Security Administration (SSA) is soliciting comments on information collections related to supportive housing and employment initiatives for homeless individuals. The SHIPS study aims to determine the effectiveness of combining Individual Placement and Support (IPS) services with supportive housing to improve employment outcomes, income, and self-sufficiency.

Learn More